Recordati Industria Chimica e Farmaceutica SPA (RECN) Ratios
Recordati Industria Chimica e Farmaceutica SPA Ratios
MX:RECN's free cash flow for Q2 2026 was $207.46M. For the 2026 fiscal year, MX:RECN's free cash flow was decreased by $-9.63M and operating cash flow was $217.09M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.59 | 1.61 | 1.20 | 1.28 | 1.36 |
| Quick Ratio | 1.08 | 1.06 | 0.79 | 0.82 | 0.99 |
| Cash Ratio | 0.41 | 0.35 | 0.22 | 0.31 | 0.39 |
| Solvency Ratio | 0.20 | 0.18 | 0.21 | 0.18 | 0.34 |
| Operating Cash Flow Ratio | 0.57 | 0.61 | 0.48 | 0.50 | 0.78 |
| Short-Term Operating Cash Flow Coverage | 1.77 | 1.87 | 4.86 | 1.21 | 2.12 |
| Net Current Asset Value | $ -1.65B | $ -1.77B | $ -1.32B | $ -1.27B | $ -584.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.47 | 0.48 | 0.35 | 0.43 | 0.35 |
| Debt-to-Equity Ratio | 1.29 | 1.33 | 0.87 | 1.11 | 0.72 |
| Debt-to-Capital Ratio | 0.56 | 0.57 | 0.46 | 0.53 | 0.42 |
| Long-Term Debt-to-Capital Ratio | 0.52 | 0.53 | 0.44 | 0.46 | 0.35 |
| Financial Leverage Ratio | 2.74 | 2.74 | 2.50 | 2.59 | 2.04 |
| Debt Service Coverage Ratio | 1.72 | 1.72 | 3.48 | 1.13 | 2.01 |
| Interest Coverage Ratio | 7.25 | 7.83 | 7.49 | 13.54 | 27.94 |
| Debt to Market Cap | 0.24 | 0.23 | 0.14 | 0.21 | 0.08 |
| Interest Debt Per Share | 12.49 | 12.46 | 7.48 | 8.51 | 4.90 |
| Net Debt to EBITDA | 2.30 | 2.73 | 1.75 | 2.56 | 1.29 |
| Profitability Margins | |||||
| Gross Profit Margin | 68.27% | 68.34% | 68.32% | 69.42% | 72.93% |
| EBIT Margin | 25.99% | 26.83% | 27.16% | 23.40% | 30.43% |
| EBITDA Margin | 33.88% | 33.97% | 34.01% | 30.18% | 36.60% |
| Operating Profit Margin | 27.49% | 27.29% | 26.80% | 23.60% | 31.02% |
| Pretax Profit Margin | 22.20% | 23.37% | 23.58% | 21.66% | 29.32% |
| Net Profit Margin | 16.94% | 17.79% | 18.69% | 16.85% | 24.43% |
| Continuous Operations Profit Margin | 16.94% | 17.79% | 18.69% | 16.85% | 24.43% |
| Net Income Per EBT | 76.32% | 76.12% | 79.26% | 77.80% | 83.30% |
| EBT Per EBIT | 80.76% | 85.64% | 88.00% | 91.79% | 94.52% |
| Return on Assets (ROA) | 8.45% | 8.11% | 9.25% | 7.81% | 13.71% |
| Return on Equity (ROE) | 23.11% | 22.19% | 23.08% | 20.20% | 27.94% |
| Return on Capital Employed (ROCE) | 17.14% | 15.19% | 17.41% | 14.22% | 22.39% |
| Return on Invested Capital (ROIC) | 12.11% | 10.76% | 13.34% | 9.81% | 16.86% |
| Return on Tangible Assets | 21.50% | 22.83% | 26.09% | 21.38% | 34.33% |
| Earnings Yield | 4.45% | 3.99% | 3.86% | 3.92% | 3.32% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.44 | 4.53 | 4.68 | 4.95 | 5.01 |
| Payables Turnover | 2.41 | 2.50 | 2.50 | 2.52 | 2.40 |
| Inventory Turnover | 1.54 | 1.46 | 1.63 | 1.34 | 1.87 |
| Fixed Asset Turnover | 11.78 | 11.33 | 11.66 | 11.64 | 12.05 |
| Asset Turnover | 0.50 | 0.46 | 0.49 | 0.46 | 0.56 |
| Working Capital Turnover Ratio | 4.41 | 6.15 | 9.02 | 7.63 | 7.56 |
| Cash Conversion Cycle | 167.77 | 183.83 | 155.97 | 202.20 | 116.21 |
| Days of Sales Outstanding | 82.25 | 80.55 | 78.04 | 73.80 | 72.86 |
| Days of Inventory Outstanding | 237.18 | 249.37 | 223.98 | 273.12 | 195.19 |
| Days of Payables Outstanding | 151.67 | 146.09 | 146.05 | 144.72 | 151.83 |
| Operating Cycle | 319.44 | 329.92 | 302.02 | 346.92 | 268.04 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.90 | 2.76 | 2.36 | 2.25 | 2.39 |
| Free Cash Flow Per Share | 2.49 | 2.59 | 0.50 | 1.78 | 1.96 |
| Dividend Paid and CapEx Coverage Ratio | 1.69 | 1.96 | 0.77 | 1.41 | 1.62 |
| Capital Expenditure Coverage Ratio | 7.01 | 15.55 | 1.27 | 4.79 | 5.63 |
| Operating Cash Flow Coverage Ratio | 0.24 | 0.23 | 0.33 | 0.27 | 0.50 |
| Operating Cash Flow to Sales Ratio | 0.23 | 0.24 | 0.23 | 0.25 | 0.31 |
| Free Cash Flow Yield | 5.13% | 5.13% | 1.01% | 4.59% | 3.47% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 22.47 | 25.05 | 25.89 | 25.51 | 30.16 |
| Price-to-Sales (P/S) Ratio | 3.81 | 4.46 | 4.84 | 4.30 | 7.37 |
| Price-to-Book (P/B) Ratio | 5.20 | 5.56 | 5.97 | 5.15 | 8.42 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 19.49 | 19.51 | 98.73 | 21.80 | 28.79 |
| Price-to-Operating Cash Flow Ratio | 16.71 | 18.32 | 20.76 | 17.25 | 23.67 |
| Price-to-Earnings Growth (PEG) Ratio | 3.24 | 3.64 | 1.06 | -1.36 | 3.73 |
| Enterprise Value Multiple | 13.54 | 15.85 | 15.98 | 16.80 | 21.42 |
| Enterprise Value | 12.01B | 12.61B | 11.32B | 9.40B | 12.39B |
| EV to EBITDA | 13.54 | 15.85 | 15.98 | 16.80 | 21.42 |
| EV to Sales | 4.59 | 5.38 | 5.44 | 5.07 | 7.84 |
| EV to Free Cash Flow | 23.47 | 23.56 | 110.90 | 25.72 | 30.64 |
| EV to Operating Cash Flow | 20.13 | 22.12 | 23.32 | 20.36 | 25.20 |
| Tangible Book Value Per Share | -6.18 | -6.95 | -5.01 | -4.83 | -1.51 |
| Shareholders’ Equity Per Share | 9.34 | 9.10 | 8.20 | 7.52 | 6.71 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | 0.24 | 0.21 | 0.22 | 0.17 |
| Revenue Per Share | 12.74 | 11.35 | 10.13 | 9.01 | 7.67 |
| Net Income Per Share | 2.16 | 2.02 | 1.89 | 1.52 | 1.87 |
| Tax Burden | 0.76 | 0.76 | 0.79 | 0.78 | 0.83 |
| Interest Burden | 0.85 | 0.87 | 0.87 | 0.93 | 0.96 |
| Research & Development to Revenue | 0.13 | 0.12 | 0.12 | 0.12 | 0.11 |
| SG&A to Revenue | 0.28 | 0.28 | 0.06 | 0.06 | 0.05 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Income Quality | 1.35 | 1.37 | 1.25 | 1.48 | 1.27 |
Currency in EUR